🇺🇸 FDA
Pipeline program

PEMBROLIZUMAB, DARAXONRASIB (RMC-6236), CARBOPLATIN, DARAXONRASIB (RMC-6236), PEMETREXED, CISPLATIN, RMC-9805

RMC-LUNG-101C

Phase 2 small_molecule active

Quick answer

PEMBROLIZUMAB, DARAXONRASIB (RMC-6236), CARBOPLATIN, DARAXONRASIB (RMC-6236), PEMETREXED, CISPLATIN, RMC-9805 for Lung Cancer is a Phase 2 program (small_molecule) at Revolution Medicines with 1 ClinicalTrials.gov record(s).

Program details

Company
Revolution Medicines
Indication
Lung Cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials